An­oth­er Flag­ship-found­ed biotech shut­ters as Ax­cel­la liq­ui­dates, end­ing long Covid plans

An­oth­er Flag­ship Pi­o­neer­ing-found­ed biotech will shut­ter, as 12-year-old Ax­cel­la dis­closed that its stock­hold­ers over­whelm­ing­ly ap­proved its dis­so­lu­tion and liq­ui­da­tion on Mon­day, per an SEC fil­ing.

The move comes as lit­tle sur­prise as the Boston-area biotech let go of near­ly all em­ploy­ees and sought strate­gic al­ter­na­tives 12 months ago. In Jan­u­ary of 2023, Ax­cel­la had still tried to move for­ward with late-stage test­ing of a treat­ment can­di­date for long Covid, which had failed an ear­li­er tri­al and was pre­vi­ous­ly in­ves­ti­gat­ed for the fat­ty liv­er dis­ease known as non­al­co­holic steato­hep­ati­tis, or NASH. But to push for­ward, it would need fund­ing and ex­ter­nal help, which nev­er came its way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER